Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$11.83 USD
-0.65 (-5.21%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $11.90 +0.07 (0.59%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RNAC 11.83 -0.65(-5.21%)
Will RNAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAC
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
Other News for RNAC
Cartesian Therapeutics (RNAC) Grants Stock Options to New Employees
Cartesian Therapeutics announces new employment inducement grants
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News
Cartesian: Autoimmune Cell Therapy Excites, But Reality Bites
RNAC: Wedbush Foresees Promising Future for Cartesian Therapeutics | RNAC Stock News